Bertin, Berangere
Veron, Philippe
Leborgne, Christian
Deschamps, Jack-Yves
Moullec, Sophie
Fromes, Yves
Collaud, Fanny
Boutin, Sylvie
Latournerie, Virginie
van Wittenberghe, Laetitia
Delache, Benoit
Le Grand, Roger
Dereuddre-Bosquet, Nathalie
Benveniste, Olivier
Moullier, Philippe
Masurier, Carole
Merten, Otto
Mingozzi, Federico
Funding for this research was provided by:
Genethon
Agence Nationale de la Recherche (ANR-10-EQPX-02-01, ANR-10-EQPX-02-01, ANR-10-EQPX-02-01)
Article History
Received: 7 October 2019
Accepted: 3 January 2020
First Online: 21 January 2020
Competing interests
: O.M. and F.M. are inventors in patent describing methods to modulate immune responses to AAV and to prevent or remove anti-AAV antibodies. F.M. is employee and equity holder of Spark Therapeutics. P.M. is employee and equity holder of Ask Bio. C.M. is employee of Genosafe. O.M. is employee of Miltenyi Biotech. All other authors declare no competing interests.